Loading patent…
AssigneeZymoGenetics, Inc.
InventorsKevin M. Klucher, Wayne R. Kindsvogel, Pallavur V. Sivakumar, Katherine E. Henderson
Estimating the term…
IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
A method of treating a hepatitis C infection in a mammal comprising administering to the mammal a therapeutically effective amount of an isolated polypeptide comprising amino acid residues 1-176 of SEQ ID NO:134 in combination with a protease inhibitor, wherein after administration of the polypeptide and protease inhibitor the viral load is reduced.
A method of treating a hepatitis C infection in a mammal comprising administering to the mammal a therapeutically effective amount of a composition comprising:
Dependencies are inferred from the claim text.